Liver Cancer Caused by Alcohol Consumption May Have Worse Prognosis than Other Forms

Release Date: Wednesday, March 28, 2018 8:26 am EDT

Terms: American Cancer Society Cancer Health Sciences

Dateline City: Hoboken, NJ

Contacts: Dawn Peters (US) +1 781-388-8408 sciencenewsroom@wiley.com Follow us on Twitter @WileyNews

A new study indicates that patients with alcohol-related liver cancer often do not live as long as patients with liver cancer that is not associated with alcohol consumption, mainly due to diagnoses at later stages. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings indicate that efforts should be made to improve both screening for early signs of liver cancer and the management of alcohol abuse.

Liver cancer is the second leading cause of cancer-related deaths worldwide, with hepatitis B and C infections being the main causes. Alcohol abuse and non-alcoholic fatty liver disease are other dominant risk factors. Due to improvements in the treatment of hepatitis infections and increased alcohol consumption in some regions, it is likely that alcohol will become a leading cause of liver cancer in the near future. Indeed, alcohol is already the first cause of liver cancer in France and involved in 25 percent to 30 percent of diagnoses in the United States. The real US figure is likely higher as alcohol consumption is often underreported when another risk factor is present.

To compare aspects of alcohol-related and non-alcohol–related liver cancer, Charlotte Costentin, MD, of Hôpital Henri-Mondor in France, and her colleagues examined 894 patients with newly diagnosed liver cancer who were followed for 5 years; 582 patients (65 percent) had a history of chronic alcohol abuse and 312 (35 percent) did not. Investigators also recorded whether patients with alcohol-related liver cancer were abstinent or not at the time of cancer diagnosis.

A total of 601 patients had died by the time of the investigators’ final analyses. Alcohol-related liver cancers were more likely to be diffuse and were detected in patients with worse liver function. Median overall survival was 9.7 versus 5.7 months in the non-alcohol–related and alcohol-related groups respectively. When investigators looked at each stage of cancer individually, however, survival was similar in patients with non-alcohol-related and alcohol-related cancer. The findings suggest that patients with alcohol-related liver cancer have a reduced overall survival mainly due to worse liver function and tumor characteristics at diagnosis.

The analysis also examined whether patients were participating in cirrhosis follow-up programs before their cancers were diagnosed. (Most people who develop liver cancer show signs of scarring, or cirrhosis, in the liver, and international guidelines recommend ultrasound every six months to detect early liver cancer in patients with cirrhosis.) Patients whose liver cancer was detected during a cirrhosis follow-up program had improved survival compared with patients whose cancer was diagnosed incidentally. This was especially pronounced in patients with non-alcohol-related liver disease or those with alcohol-related liver disease who are no longer drinking alcohol compared with non-abstinent patients. Also, non-abstinent alcoholic patients had the lowest survival in the study, even when restricting the analysis to patients involved in cirrhosis follow-up programs.

“To improve prognosis of liver cancer in the alcoholic population, efforts should be made to implement effective screening programs for both cirrhosis and liver cancer, and to improve access to alcoholism treatment services,” said Dr. Costentin. “A smaller tumor burden and a better liver function at diagnosis should translate into higher rates of patients with alcohol-related liver cancer amenable to curative treatment such as tumor resection or ablation and liver transplantation.”

Additional Information

Full Citation: “Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: results of a prospective nationwide study.” Charlotte E. Costentin, Abbas Mourad, Pierre Lahmek, Xavier Causse, Alexandre Pariente, Hervé Hagège, Anca Steila Dobrin, Claire Becker, Béрагère Marks, Robert Bader, Bertrand Condat, Frédéric Héluwaert, Jean François Seltz, Bruno Lesgourgues, Jacques Denis, Sylvie Deuffic-Burban, Isabelle Rosa, and Thomas Decaens on behalf of CHANGH study group. CANCER; Published Online: March 28, 2018 (DOI: 10.1002/cncr.31215).


Author Contact: Press office of the Assistance Publique Hôpitaux de Paris, at service.presse@aphp.fr or 01 40 27 37 22.

About the Journal